BRIEF—New approval in Japan for Takeda's Entyvio

Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved the use of Takeda’s Entyvio (vedolizumab) Pens for subcutaneous (SC) injection 108mg / Syringes for SC injection 108mg as maintenance therapy for moderate to severe ulcerative colitis.

Entyvio should be used only in patients with inadequate response to conventional treatment, Takeda noted.

“We are delighted that the subcutaneous formulation of Entyvio has been approved. We believe that this approval will provide a wider range of dosing options for ulcerative colitis patients and healthcare professionals and will help meet their diverse needs and improve quality of life,” said Naoyoshi Hirota, general manager of Takeda Development Center Japan.